ArticleFrontiers in physiology2026
The value of renal biopsy in PLA
Article in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The detection of serum anti-phospholipase A Methods: This study aimed to evaluate the value of renal biopsy in the diagnosis, treatment and prognosis of patients with proteinuria who are seropositive for PLA Results: Renal biopsy was performed in 414 SAb+ patients, 284 patients with primary membranous nephropathy (PMN) alone, 11 patients with atypical MN (AMN), 119 patients with PMN and diabetes mellitus (DM) or other pathologies, such as obesity-related glomerulopathy (ORG), renal tubular/interstitial injury (RTI), and ischemic kidney injury (IRI). There was no significant difference in the treatment or prognoses of MN patients with or without additional pathologies/DM. A high estimated glomerular filtration rate (eGFR) was associated with favorable prognosis (P<0.05), but additional pathologies were not significantly associated with it (P>0.05). Discussion: In conclusion, SAb+ can strongly predict MN (including in patients with DM) in China, but often coexists with additional pathologies. The presence of additional pathologies did not appear to be a significant determinant of management or prognosis. Renal biopsy is still necessary for accurate diagnosis, especially in patients with renal dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.